M
MBX Biosciences Inc
NASDAQ:MBX
MBX Biosciences Inc
NASDAQ:MBX
Price:
36.75
USD
5.63%
Market Cap:
$1.7B
Relative Value
There is not enough data to reliably calculate the relative value of MBX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MBX
Relative Value
Base Case
Not Available
Multiples Across Competitors
MBX Competitors Multiples
MBX Biosciences Inc Competitors
MBX Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
M
|
MBX Biosciences Inc
NASDAQ:MBX
|
1.6B USD | 0 | -20.4 | -13.8 | -13.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
979.9B USD | 15.3 | 48.2 | 32.4 | 34.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.5B USD | 6.3 | 22.1 | 15.4 | 18.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
298.2B CHF | 4.9 | 31.7 | 13.3 | 15.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
240.7B GBP | 5.5 | 31.8 | 17.5 | 24.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
247.5B CHF | 5.7 | 22.8 | 14 | 18.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
306.4B USD | 4.7 | 16.9 | 10.5 | 12.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.7 | 7.9 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
155.3B USD | 2.5 | 19.9 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.2B USD | 2.6 | 17.5 | 7.3 | 9.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
